RESUMEN
BACKGROUND: Transcarotid artery revascularization (TCAR) is growing in popularity. Although major clinical end-points such as stroke rate and mortality are well-known, patient reported outcomes such as pain, and length of stay are among the purported benefits that are as yet untested. We sought to determine if there are differences in pain and other clinical outcomes when comparing carotid endarterectomy (CEA) and TCAR. METHODS: We performed a retrospective review of 326 patients undergoing TCAR (n = 50) or CEA (n = 276) from 2019-2023. Primary outcomes of interest were maximum pain numeric rating scales (NRS) reported in the post-anesthesia care unit (PACU) and on postoperative days (POD) zero and 1, and oral morphine milligram equivalents (OMMEs) received intraoperatively through POD1. Secondary outcomes included length of stay (LOS), complications, and 30-day emergency department (ED) returns/readmissions. RESULTS: Fifty TCAR and 150 CEA patients were included in the propensity score matched cohorts. TCAR patients reported lower pain-NRS in PACU (P < .001) and on POD0 (P = .002), but similar pain scores on POD1 (P = .112). Postoperatively, TCAR patients were less likely to receive opioids (52% vs 75.3%, P = .003) and received less OMME from PACU through POD1 (12.8 ± 16.2 vs 23.2 ± 27.2, P = .001). After adjusting for age, sex, BMI, prior chronic opioid use, and prior carotid surgery, TCAR patients were approximately 70% less likely to receive post-operative opioids. No significant differences in LOS, 30-day ED returns/readmissions, or complications were observed between groups. CONCLUSIONS: Compared with CEA, patients undergoing TCAR reported lower pain scores and consumed fewer narcotics overall. However, the absolute difference was modest, and pain scores were low in both cohorts. Differences in pain and post-operative narcotic use may be of less importance when deciding between TCAR and CEA. Total non-opioid protocols may be feasible in both approaches.
Asunto(s)
Endarterectomía Carotidea , Tiempo de Internación , Dimensión del Dolor , Dolor Postoperatorio , Humanos , Endarterectomía Carotidea/efectos adversos , Endarterectomía Carotidea/mortalidad , Masculino , Femenino , Estudios Retrospectivos , Dolor Postoperatorio/etiología , Dolor Postoperatorio/diagnóstico , Anciano , Resultado del Tratamiento , Factores de Tiempo , Persona de Mediana Edad , Factores de Riesgo , Procedimientos Endovasculares/efectos adversos , Procedimientos Endovasculares/mortalidad , Analgésicos Opioides/uso terapéutico , Anciano de 80 o más Años , Medición de Riesgo , Enfermedades de las Arterias Carótidas/cirugía , Enfermedades de las Arterias Carótidas/mortalidad , Enfermedades de las Arterias Carótidas/complicaciones , Enfermedades de las Arterias Carótidas/diagnóstico por imagen , Estenosis Carotídea/cirugía , Estenosis Carotídea/mortalidad , Estenosis Carotídea/complicaciones , Estenosis Carotídea/diagnóstico por imagenRESUMEN
BACKGROUND: Our primary objective was to determine the relationship between plasma fibrinogen levels (PFLs) and major bleeding complications during catheter-directed thrombolysis, including final, nadir, and change over time. Furthermore, we sought to evaluate additional predictors of bleeding outcomes, including duration of lysis and total dose of tissue plasminogen activator received. METHODS: In this multicenter retrospective cohort study, we reviewed all patients undergoing catheter-directed thrombolysis between January 2016 and August 2021. Patients undergoing thrombolysis for management of peripheral arterial or venous thromboses, as well as for submassive pulmonary embolism, were included. We examined the relationships between PFLs during catheter-directed lysis and the incidence of major bleeding-that is significant hemorrhage requiring transfusion, intracranial hemorrhage, or hemorrhage requiring adjunctive procedures. We also examined the duration of lysis and total lytic agent dose received to assess for association with major bleeding. RESULTS: A total of 438 patients underwent catheter-directed lysis from January 1, 2016 through August 21, 2021, with a major bleeding rate of 16%. Patients who experienced major bleeding were more likely to be older (P = 0.022), experience in-stent thrombosis (P = 0.041), or have thrombosis in a lower extremity vessel (P = 0.011). There was no association between the incidence of major bleeding and a nadir PFL of <150 mg/dL (P = 0.194). Those who experienced major bleeding complications had a significantly greater decrease in PFL from baseline to nadir. This was true for both absolute (P = 0.029) and relative (P = 0.034) PFL decrease. Only percent decrease remained a significant predictor when adjusting for age, thrombosis type, and thrombosis location (P = 0.041). The PFL changes that were the best predictors of major bleeding complications were an absolute decrease of 146 mg/dL, or a relative decrease of 47%, giving a sensitivity and specificity of 71% and 48%, respectively. If neither were true, the negative predictive value for major bleeding was 89% regardless of absolute PFL. CONCLUSIONS: In this large, multicenter cohort, there does not appear to be an association between absolute PFL and major bleeding during catheter-directed lysis. Specifically, the typical absolute threshold of < 150 mg/dL was not an independent predictor of major bleeding. There was an association between percent-change in plasma fibrinogen and major bleeding, which aligns with the underlying physiologic mechanism of fibrinogen degradation coagulopathy. Applying a so-called "50-150 Rule" to catheter-directed lysis may decrease bleeding complications. That is, continued lysis should be re-evaluated if PFL drops by ≥150 mg/dL or by ≥50% from baseline regardless of absolute PFL.
Asunto(s)
Hemostáticos , Trombosis , Humanos , Activador de Tejido Plasminógeno , Fibrinolíticos/efectos adversos , Fibrinógeno/metabolismo , Terapia Trombolítica/efectos adversos , Terapia Trombolítica/métodos , Estudios Retrospectivos , Resultado del Tratamiento , Hemorragia/inducido químicamente , Hemostáticos/uso terapéutico , Trombosis/etiología , Trombosis/terapia , Catéteres , Estudios Multicéntricos como AsuntoRESUMEN
BACKGROUND: Prior studies have demonstrated the value of live streamed surgical procedures in surgical education and that learning is further enhanced with the use of 360-degree video. Emerging virtual reality (VR) technology now offers yet another advancement by placing learners in an immersive environment, which can improve both engagement and procedural learning. AIMS: The aim here is to test the feasibility of live streaming surgery in immersive virtual reality using consumer-level technology, including stream stability and impacts on case duration. METHODOLOGY: Ten laparoscopic procedures were live-streamed in a 360-degree immersive VR format over a 3-week period for viewing by surgical residents in a remote location wearing a head-mounted display. Stream quality, stability and latency were monitored, and operating room time was compared to non-streamed surgeries to quantify impacts on procedure times. CONCLUSIONS: This novel live streaming configuration was able to deliver high-quality, low-latency video directly to a VR platform, allowing complete immersion into the learning environment by remote learners. Live streaming surgical procedures in an immersive VR format provides an efficient, cost-effective, and reproducible way to teleport remote learners from any location directly into the operating room.